HPV vaccination: For women of all ages?

The Lancet

Volumn 384, Issue 9961, 2014, Pages 2178-2180

  Castle, Philip E ^a   Schmeler, Kathleen M ^b  

^a Global Coalition Against Cervical Cancer   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; WART VIRUS VACCINE;

FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

ADJUVANTS, IMMUNOLOGIC; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84919391223     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61230-7     Document Type: Note

References (16)

1. M Schiffman, PE Castle The promise of global cervical-cancer prevention N Engl J Med 353 2005 2101 2104
2. SR Skinner, A Szarewski, B Romanowski for the VIVIANE Study Group Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study Lancet 2014 published online Sept 2. http://dx.doi.org/10.1016/S0140-6736(14)60920-X
3. LE Markowitz, EF Dunne, M Saraiya, HW Lawson, H Chesson, ER Unger Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 56 RR-2 2007 1 24
4. M Lehtinen, J Paavonen, CM Wheeler et al. Overall efficacy of HPV 16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol 13 2012 89 99
5. X Castellsagué, N Munoz, P Pitisuttithum et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age Br J Cancer 105 2011 28 37
6. SK Kjaer, K Sigurdsson, OE Iversen et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions Cancer Prev Res (Phila) 2 2009 868 878
7. R Herrero, S Wacholder, AC Rodriguez et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica Cancer Discov 1 2011 408 419
8. PE Castle, AC Rodriguez, RD Burk et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study BMJ 339 2009 b2569
9. SK Kjaer, K Frederiksen, C Munk, T Iftner Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence J Natl Cancer Inst 102 2010 1478 1488
10. HA Katki, M Schiffman, PE Castle et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive J Low Genit Tract Dis 17 5 suppl 1 2013 S56 S63
11. S Franceschi, L Denny, KL Irwin et al. EUROGIN 2010 roadmap on cervical cancer prevention Int J Cancer 128 2011 2765 2774
12. Castellsagué X, Bruni L, de Sanjose S, Bosch FX. Other potential indications and targets for HPV vaccination: the case of mid-adult women. EUROGIN Congress 2013, Florence, Italy; Nov 3-6, 2013. Report No SS 23-4 (abstr).
13. Joura EA, on behalf of the V503-001 study team. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. EUROGIN Congress 2013, Florence, Italy; Nov 3-6, 2013. Report No SS 8-4 (abstr).
14. S de Sanjose, WG Quint, L Alemany on behalf of the Retrospective International Survey and HPV Time Trends Study Group Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study Lancet Oncol 11 2010 1048 1056
15. AF Rositch, AE Burke, RP Viscidi, MI Silver, K Chang, PE Gravitt Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women Cancer Res 72 2012 6183 6190
16. CM Wheeler, WC Hunt, NE Joste, CR Key, WG Quint, PE Castle Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States J Natl Cancer Inst 101 2009 475 487